ClinicalTrials.gg
Status unknownNCT02140489Updated May 16, 2014

Evaluating a Pharmacokinetic Drug Interaction Between Amlodipine/Losartan and Rosuvastatin

A Phase 1 interventional study of amosartan and rosuvastatin in Healthy, sponsored by Hanmi Pharmaceutical Company Limited. Status unknown at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-16.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified May 2014), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the drug-drug interaction between amlodipine/losartan and rosuvastatin in healthy male volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male
  • Age between 19 and 55
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Presence of medical history or a concurrent disease
  • Has a history of to IP ingredients
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Sequence 1

    amosartan → rosuvastatin → amosartan and rosuvastatin

    Drug: amosartan · Drug: rosuvastatin · Drug: amosartan and rosuvastatin

  • Experimental
    Sequence 2

    rosuvastatin → amosartan and rosuvastatin → amosartan

    Drug: amosartan · Drug: rosuvastatin · Drug: amosartan and rosuvastatin

  • Experimental
    Sequence 3

    amosartan and rosuvastatin → amosartan → rosuvastatin

    Drug: amosartan · Drug: rosuvastatin · Drug: amosartan and rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Time frame: 0-72h

  2. AUClast

    Time frame: 0-72h

Secondary outcomes

  1. tmax

    Time frame: 0-72h

  2. t1/2

    Time frame: 0-72h

  3. AUCinf

    Time frame: 0-72h

07

Study locations

1 of 1 sites recruiting
  • Samgsung Seoul Hospital
    Seoul, Korea, Republic of
    Recruiting
    • JaeWook Ko, M.D. · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of May 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2014
First posted
May 16, 2014
Start
Feb 2014
Primary completionEst.
May 2014
CompletionEst.
Aug 2014
Last update
May 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02140489
Responsible party
Sponsor
First posted
May 16, 2014
Start date
Feb 2014
Primary completion
May 2014 (estimated)
Completion
Aug 2014 (estimated)
Last update
May 16, 2014

Study contacts

Jin-A Jung, Ph.D
Contact
jajung@hanmi.co.kr
JaeWook Ko, M.D.
principal investigator · Samsung Seoul Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion